Regenicin (RGIN) Stock Price, News & Analysis

Company Overview

Regenicin, Inc. is a biotechnology company focused on regenerative medicine and tissue-engineering technologies. The company has concentrated on developing products intended to help repair or replace damaged human tissue, particularly skin.

Its principal product candidate has been PermaDerm™, a tissue-engineered skin substitute designed for applications including the treatment of severe burns and other serious skin wounds. The technology is intended to support the regeneration of functional skin and address situations in which conventional wound-care methods may be insufficient.

Regenicin was formerly known as Entest Group, Inc. before adopting its current name. Publicly available information provides limited detail about the company’s current leadership, commercial operations, and geographic markets served.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $20 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/19/2020
• Today: 10/15/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:RGIN
• CIK: 1412659
• Web: www.regenicin.com
• Phone: (732) 757-5500
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 165,770,000
• Free Float: N/A
• Market Cap: $20 thousand
• Optionable: Not Optionable
• Beta: N/A